These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. Pain C; Dumont J; Dumoulin M Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912 [TBL] [Abstract][Full Text] [Related]
4. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis]. Yoshida K; Higuchi K; Ikeda S Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474 [TBL] [Abstract][Full Text] [Related]
5. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Meredith SC Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927 [TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. Naiki H; Nagai Y J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812 [TBL] [Abstract][Full Text] [Related]
7. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease. Jeffrey M Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056 [TBL] [Abstract][Full Text] [Related]
8. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Bayer TA Eur Neuropsychopharmacol; 2015 May; 25(5):713-24. PubMed ID: 23642796 [TBL] [Abstract][Full Text] [Related]
10. [Amyloid aggregates: role in Protein Misfolding Disorders]. Duran-Aniotz C; Moreno-Gonzalez I; Morales R Rev Med Chil; 2013 Apr; 141(4):495-505. PubMed ID: 23900371 [TBL] [Abstract][Full Text] [Related]
11. Protein conformational diseases: from mechanisms to drug designs. Lin JC; Liu HL Curr Drug Discov Technol; 2006 Jun; 3(2):145-53. PubMed ID: 16925522 [TBL] [Abstract][Full Text] [Related]
12. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases. Ries HM; Nussbaum-Krammer C Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334 [TBL] [Abstract][Full Text] [Related]
13. [Neurodegenerative conformational disease and its molecular bases]. Li WW; Cai DF; Ren HM Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610 [TBL] [Abstract][Full Text] [Related]
14. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032 [TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical insights into protein misfolding and associated amyloidosis. Pande M; Srivastava R Eur J Med Chem; 2019 Dec; 184():111753. PubMed ID: 31622853 [TBL] [Abstract][Full Text] [Related]
17. Protein folding, misfolding and aggregation: A tale of constructive to destructive assembly. Khan MV; Zakariya SM; Khan RH Int J Biol Macromol; 2018 Jun; 112():217-229. PubMed ID: 29374532 [TBL] [Abstract][Full Text] [Related]